Pay-For-Delay Antitrust Suits May Settle More Often After Jury Verdict For AstraZeneca

Jury finds AstraZeneca’s Nexium patent infringement settlement with Ranbaxy was not antitrust violation; direct purchasers and third party payers claimed agreement was worth nearly $1 billion.